Thymoquinone Derivatives Stabilize G-Quadruplex DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents are ineffective in selectively targeting and inhibiting cancer cells while sparing normal cells, particularly in treating cancers like pancreatic, lung, and breast cancer, due to the overexpression of the telomerase enzyme in cancer cells which maintains telomere length and allows for indefinite cell division.
Innovation Solution
Development of substituted thymoquinone derivatives that selectively bind and stabilize G-quadruplex DNA structures, inhibiting the telomerase enzyme and thereby inhibiting cancer cell proliferation, which are administered alone or in combination with other anti-tumor agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticancer agents are used, then cancer cells are targeted, but normal cells are also damaged due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing thymoquinone derivatives with specific molecular structures (substituents at positions 2 and 5 of the benzoquinone ring) that enable selective binding to G-quadruplex DNA structures. This selective binding property allows the compound to differentiate between cancer cells (which have high telomerase activity and G-quadruplex structures) and normal cells, thereby achieving localized action at the molecular level while sparing normal cells from damage.
2Reliability
If thymoquinone derivatives are designed to bind G-quadruplex DNA, then telomerase activity is inhibited, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the molecular parameters of thymoquinone derivatives, specifically varying the substituents at positions 2 and 5 of the benzoquinone ring (such as alkyl groups, aryl groups, heteroaryl groups). These parameter changes optimize the compound's ability to bind G-quadruplex DNA and inhibit telomerase activity while managing molecular complexity through structured variation of substituent types and positions.
3Productivity
If small molecules are designed to stabilize G-quadruplex DNA, then cancer cell proliferation is inhibited, but drug development difficulty increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the core thymoquinone benzoquinone ring system and the variable substituent groups at positions 2 and 5. This segmented approach allows for systematic exploration of structure-activity relationships by independently varying substituent parameters, thereby facilitating drug development through modular design while maintaining the ability to inhibit cancer cell proliferation through G-quadruplex stabilization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The thymoquinone derivatives effectively inhibit cancer cell viability and telomerase activity, demonstrating potential as therapeutic agents for pancreatic, lung, and breast cancer treatments by selectively targeting cancer cells and stabilizing G-quadruplex DNA structures, thereby offering a promising approach to cancer therapy.
Implementation Method 1
Small molecules that bind and stabilise G-quadruplex DNA have been found to inhibit the telomerase enzyme in cancer cells
Data Source
AI summary
The present invention describes thymoquinone compounds formula (I): (i) These compounds have been identified as being useful in the treatment of cancer.